- Home
- KYNB vs MIRA Comparison
KYNB vs MIRA Comparison
Compare KYNB & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | MIRA |
|---|---|---|
| Founded | 1993 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 32.1M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KYNB | MIRA |
|---|---|---|
| Price | $7.87 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.1K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9552.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $0.60 |
| 52 Week High | $9.58 | $2.45 |
Technical Indicators
Market Signals| Indicator | KYNB | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 45.11 |
| Support Level | $7.40 | $0.72 |
| Resistance Level | $7.95 | $0.82 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 45.43 | 8.29 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.